A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been ... did not receive any inhaled medication. Spirometry was performed ...

This includes steroid-containing combinations and long-acting bronchodilators ... should be the foundation treatment for the majority of symptomatic COPD patients. In the CRYSTAL study, patients ...

Conclusion: Tiotropium appears to be at least as effective as currently available alternatives in the treatment of patients with COPD who require daily bronchodilator treatment. Its simplified ...

This includes steroid-containing combinations and long-acting bronchodilators ... should be the foundation treatment for the majority of symptomatic COPD patients. In the CRYSTAL study, patients ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

Traditionally, COPD management has relied on bronchodilators ... now you have an entirely new category of treatment options that are minimally invasive. There is one that's currently available ...

Current treatment options for COPD include bronchodilators such as beta2-agonists and anticholinergics, standalone or combination inhaled corticosteroids (ICS), and other combination medications.

Since COPD treatment is highly individualized ... A combination of lifestyle changes, pulmonary rehab, and treatments like bronchodilators and corticosteroids can help COPD patients live as ...

Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated ...